Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-<i>a</i>]pyrazines as ATR Inhibitors
作者:Paul A Barsanti、Robert J. Aversa、Xianming Jin、Yue Pan、Yipin Lu、Robert Elling、Rama Jain、Mark Knapp、Jiong Lan、Xiaodong Lin、Patrick Rudewicz、Janet Sim、Lorena Taricani、George Thomas、Linda Xiao、Qin Yue
DOI:10.1021/ml500353p
日期:2015.1.8
A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines. Use of PI3K alpha mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chemistry designs. Detailed DMPK studies involving cyanide and GSH as trapping agents during microsomal incubations, in addition to deuterium-labeled compounds as mechanistic probes uncovered the molecular basis for the observed CYP3A4 TDI in the series.
[EN] ISOINDOLINONE DERIVATIVES AS IRAK4 MODULATORS<br/>[FR] DÉRIVÉS D'ISOINDOLINONE UTILISÉS EN TANT QUE MODULATEURS D'IRAK4
申请人:HOFFMANN LA ROCHE
公开号:WO2018234342A1
公开(公告)日:2018-12-27
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.